Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) – Investment analysts at Cantor Fitzgerald upped their FY2018 earnings per share (EPS) estimates for Valeant Pharmaceuticals Intl in a report issued on Sunday, according to Zacks Investment Research. Cantor Fitzgerald analyst L. Chen now anticipates that the specialty pharmaceutical company will earn $3.83 per share for the year, up from their prior forecast of $3.77.
Valeant Pharmaceuticals Intl (TSE VRX) traded up C$1.12 on Wednesday, hitting C$21.98. 1,850,282 shares of the company were exchanged, compared to its average volume of 1,809,298. Valeant Pharmaceuticals Intl has a one year low of C$11.20 and a one year high of C$30.56. The company has a market capitalization of $7,260.00, a price-to-earnings ratio of 4.20 and a beta of -0.76.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.